PK of Nevirapine XR 200 mg and 300 mg vs Viramune and Nevirapine XR 400 mg

Phase 1, open-label trial of nevirapine in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity up to 144 hours and Maximum measured concentration of the analyte in plasma up to 144 hours. Started Apr 2008; status: completed.